P05198

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession IF2A_HUMAN; P05198;
Entrez ID 1965
GenBank Protein ID
GenBank Nucleotide ID
Protein Name Eukaryotic translation initiation factor 2 subunit 1 (Eukaryotic translation initiation factor 2 subunit alpha) (eIF-2-alpha) (eIF-2A) (eIF-2alpha)
Gene Name EIF2S1; EIF2A
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionFunctions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S pre-initiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B.
Sequence
(Fasta)
MPGLSCRFYQ HKFPEVEDVV MVNVRSIAEM GAYVSLLEYN NIEGMILLSE LSRRRIRSIN 60
KLIRIGRNEC VVVIRVDKEK GYIDLSKRRV SPEEAIKCED KFTKSKTVYS ILRHVAEVLE 120
YTKDEQLESL FQRTAWVFDD KYKRPGYGAY DAFKHAVSDP SILDSLDLNE DEREVLINNI 180
NRRLTPQAVK IRADIEVACY GYEGIDAVKE ALRAGLNCST ENMPIKINLI APPRYVMTTT 240
TLERTEGLSV LSQAMAVIKE KIEEKRGVFN VQMEPKVVTD TDETELARQM ERLERENAEV 300
DGDDDAEEME AKAED 316

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationNeuroblastomaA15721356
[Reference]: In NS1-expressing neuroblastoma cells, VSV replication was inhibited by IFN-beta as well as in control NB41A3 cells, and eIF-2alpha phosphorylation was blocked, suggesting that PKR activity was not involved in inhibition of viral protein synthesis.
2PhosphorylationHepatitis A virus IRESA23272212
[Reference]: This is the first observation that 2A(pro) and L(pro) exhibit opposite effects to what was previously thought to be the case in HAV IRES
3PhosphorylationNon-small cell lung cancer/carcinomaP22102852
[Reference]: We also observed that the patients with high p-PKR or p-eIF2 expression had a significantly longer median survival than those with little or no p-PKR or p-eIF2 expression (p=0.03 and p=0.032, respectively).
4PhosphorylationLung cancer/carcinomaP11956076
[Reference]: We report that Ad-mda7 induces andactivates the double-stranded RNA-dependent protein kinase (PKR), which leads to phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2alpha) and the induction of apoptosis in lung cancer cells.
5PhosphorylationBone cancerU10388536
[Reference]: Increased phosphorylation of eukaryotic initiation factor 2alpha at the G2/M boundary in human osteosarcoma cells correlates with deglycosylation of p67 and a decreased rate of protein synthesis
6PhosphorylationSigma-rectum tumourU10841309
[Reference]: The unphosphorylated and phosphorylated levels of cytoplasmic eIF2alpha, as well as the percentage of phosphorylated factor over the total, were significantly higher in stomach, colon and sigma-rectum tumours compared with normal tissue.
7PhosphorylationColon cancer/carcinomaU10841309
[Reference]: The unphosphorylated and phosphorylated levels of cytoplasmic eIF2alpha, as well as the percentage of phosphorylated factor over the total, were significantly higher in stomach, colon and sigma-rectum tumours compared with normal tissue.
8PhosphorylationGastric cancerU10841309
[Reference]: The unphosphorylated and phosphorylated levels of cytoplasmic eIF2alpha, as well as the percentage of phosphorylated factor over the total, were significantly higher in stomach, colon and sigma-rectum tumours compared with normal tissue.
9Serine PhosphorylationFibrosarcomaAS5215060162
[Reference]: Herein, we demonstrate that HPV type 18 E6 protein synthesis is rapidly repressed upon eIF2alpha phosphorylation caused by the conditional activation of the kinase.
10Serine PhosphorylationHepatocellular carcinoma/Hepatocarcinoma/HepatomaPS5224157877
[Reference]: Further, transfection of A549, SMMC-7721 and HeLa cells with the phosphorylation-mutant expression plasmid eIF2S51A, which inhibits the phosphorylation of eIF2 on Ser51, inhibited compound C-mediated apoptosis (Figure 6e). Taken together, these results suggest the phosphorylation of eIF2 is involved in part in the apoptosis of cancer cells under compound C-mediated transcriptional stress
11Serine PhosphorylationLung adenocarcinomaPS5224157877
[Reference]: Further, transfection of A549, SMMC-7721 and HeLa cells with the phosphorylation-mutant expression plasmid eIF2S51A, which inhibits the phosphorylation of eIF2 on Ser51, inhibited compound C-mediated apoptosis (Figure 6e). Taken together, these results suggest the phosphorylation of eIF2 is involved in part in the apoptosis of cancer cells under compound C-mediated transcriptional stress
12Serine PhosphorylationCervical cancer/carcinomaPS5224157877
[Reference]: Further, transfection of A549, SMMC-7721 and HeLa cells with the phosphorylation-mutant expression plasmid eIF2S51A, which inhibits the phosphorylation of eIF2 on Ser51, inhibited compound C-mediated apoptosis (Figure 6e). Taken together, these results suggest the phosphorylation of eIF2 is involved in part in the apoptosis of cancer cells under compound C-mediated transcriptional stress
13Serine PhosphorylationMammary tumor/carcinomaUS5210871861
[Reference]: On the contrary, PKR autophosphorylation and the phosphorylation of its substrate, the alpha-subunit of eIF2, is 7 - 40-fold higher in lysates prepared from breast carcinoma cell lines than in those from nontransformed epithelial cell lines.

※ Disease Cross-ref Annotation

DatabaseAnnotation
CTD (Curated)
(count: 5)
MESH:D000544 ; Alzheimer Disease
MESH:D003072 ; Cognition Disorders
MESH:D009410 ; Nerve Degeneration
MESH:D013226 ; Status Epilepticus
MESH:D012516 ; Osteosarcoma
DisGeNet (Curated)
(count: 6)
C0002395; Alzheimer's Disease
C0009241; Cognition Disorders
C0027746; Nerve Degeneration
C0029463; Osteosarcoma
C0036341; Schizophrenia
C0038220; Status Epilepticus
GWASdb
(count: 2)
rs8008724; Cisplatin and carboplatin cytotoxicity, in blood cell lines; colorectal cancer|head and neck cancer|testicular cancer|lung cancer
rs2296561; Depression (quantitative trait); mental depression

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 19)
(view all)
110       TKSKTVYSILRHVAE     dbPAF
147       DKYKRPGYGAYDAFK     dbPAF
150       KRPGYGAYDAFKHAV     dbPAF
158       DAFKHAVSDPSILDS     dbPAF
161       KHAVSDPSILDSLDL     dbPAF
185       NNINRRLTPQAVKIR     dbPAF
Acetylation
(count: 9)
(view all)
101       EAIKCEDKFTKSKTV     PLMD
12        SCRFYQHKFPEVEDV     PLMD
123       AEVLEYTKDEQLESL     PLMD
141       TAWVFDDKYKRPGYG     PLMD
143       WVFDDKYKRPGYGAY     PLMD
276       FNVQMEPKVVTDTDE     PLMD
Ubiquitination
(count: 20)
(view all)
101       EAIKCEDKFTKSKTV     PLMD
104       KCEDKFTKSKTVYSI     PLMD
106       EDKFTKSKTVYSILR     PLMD
12        SCRFYQHKFPEVEDV     PLMD
123       AEVLEYTKDEQLESL     PLMD
141       TAWVFDDKYKRPGYG     PLMD
Malonylation
(count: 2)
106       EDKFTKSKTVYSILR     PLMD
61        RRIRSINKLIRIGRN     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
B5MEG8P05198IntAct
C9J6D7P05198BioGRID
E7EWZ3P05198BioGRID
E9PAL0P05198BioGRID
E9PBE3P05198BioGRID
E9PFT6P05198BioGRID
E9PHD8P05198BioGRID
E9PSH8P05198BioGRID
F5H146P05198BioGRID
F5HB16P05198BioGRID
F8WCM3P05198BioGRID
G5EA36P05198BioGRID
H0Y8F6P05198BioGRID
H0YFN3P05198BioGRID
H0YME5P05198HPRD
O00327P05198BioGRID
O43172P05198BioGRID
O43422P05198HPRD
O60575P05198BioGRID
O60739P05198IntAct
O60779P05198BioGRID
O75807P05198HPRD
O94813P05198BioGRID
O95067P05198BioGRID
P00480P05198BioGRID
P01737P05198BioGRID
P01860P05198BioGRID
P02511P05198BioGRID
P02647P05198BioGRID
P02735P05198BioGRID
P02768P05198BioGRID
P02818P05198BioGRID
P03897P05198BioGRID
P04234P05198BioGRID
P04406P05198BioGRID
P04436P05198BioGRID
P05026P05198BioGRID
P05198P05198BioGRID
P05198P06870BioGRID
P05198P07237HPRD
P05198P07900BioGRID
P05198P08574BioGRID
P05198P09038BioGRID
P05198P0DJD9BioGRID
P05198P10746BioGRID
P05198P11831BioGRID
P05198P13726BioGRID
P05198P14416BioGRID
P05198P15170BioGRID
P05198P15428BioGRID
P05198P17252MINT
P05198P17509BioGRID
P05198P17540BioGRID
P05198P18462BioGRID
P05198P18463BioGRID
P05198P19525HPRD; IntAct; MINT
P05198P20042HPRD; IntAct
P05198P20366BioGRID
P05198P20594BioGRID
P05198P30542BioGRID
P05198P31947HPRD
P05198P32242BioGRID
P05198P36873IntAct
P05198P38606BioGRID
P05198P41091IntAct
P05198P42574HPRD
P05198P42766BioGRID
P05198P43146IntAct
P05198P47813HPRD
P05198P49619BioGRID
P05198P49770HPRD
P05198P50748BioGRID
P05198P51858IntAct
P05198P55212HPRD
P05198P60413BioGRID
P05198P61011BioGRID
P05198P62805BioGRID
P05198P62873BioGRID
P05198P63261BioGRID
P05198P68104BioGRID
P05198P68400IntAct
P05198P78344MINT
P05198P78352MINT
P05198P98088BioGRID
P05198Q02817BioGRID
P05198Q05655HPRD
P05198Q08289BioGRID
P05198Q08554BioGRID
P05198Q14232HPRD
P05198Q14565BioGRID
P05198Q14680HPRD
P05198Q156A1BioGRID
P05198Q15723BioGRID
P05198Q17RH7BioGRID
P05198Q3KQU3BioGRID
P05198Q685J3BioGRID
P05198Q71DI3BioGRID
P05198Q71U36BioGRID
P05198Q75N90BioGRID
P05198Q7Z7M0BioGRID
P05198Q86UQ4BioGRID
P05198Q8N139BioGRID
P05198Q8N8E3BioGRID
P05198Q8NBK3BioGRID
P05198Q8NDC0BioGRID
P05198Q8TDC3BioGRID
P05198Q8TDT2BioGRID
P05198Q96AV8BioGRID
P05198Q96J01BioGRID
P05198Q9BQI3HPRD
P05198Q9BZ95BioGRID
P05198Q9H2G4BioGRID
P05198Q9HCC0BioGRID
P05198Q9NQW1BioGRID
P05198Q9NR50HPRD
P05198Q9NS68BioGRID
P05198Q9NWL6BioGRID
P05198Q9NX58IntAct
P05198Q9NY12BioGRID
P05198Q9NZJ5HPRD
P05198Q9UI10HPRD
P05198Q9Y4K3IntAct
P05198Q9Y5W8BioGRID
P05198Q9Y5Y3BioGRID